---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-005120"
form_type: "8-K"
ticker: "SLDB"
cik: "0001707502"
company_name: "Solid Biosciences Inc."
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:30:22.827280+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Solid Biosciences reports $210M cash, advances DMD gene therapies; names Ian Smith Executive Chair

## Summary
- Preliminary, unaudited cash and investments of ~$210M as of Dec 31, 2021.
- Ninth patient dosed in IGNITE DMD Phase I/II trial for SGT-001 in Nov 2021 using second-gen manufacturing.
- Plans to share additional SGT-001 expression, functional, pulmonary data in H1 2022.
- SGT-003 IND-enabling studies in 2022; IND filing targeted early 2023.
- Board Chair Ian F. Smith appointed Executive Chair effective Jan 10, 2022.

## SEC filing metadata
- accession: 0001193125-22-005120
- form_type: 8-K
- ticker: SLDB
- cik: 0001707502
- company_name: Solid Biosciences Inc.
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1707502/000119312522005120/0001193125-22-005120-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1707502/000119312522005120/d289427d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-005120
- JSON: https://secwatch.observer/filing/0001193125-22-005120.json
- Plain text: https://secwatch.observer/filing/0001193125-22-005120.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.